The Antidiabetic Agent Acarbose Improves Anti-PD-1 and Rapamycin Efficacy in Preclinical Renal Cancer
Open Access
Abstract
Although immune checkpoint inhibitors and targeted therapeutics have changed the landscape of treatment for renal cell carcinoma (RCC), most patients do not experience significant clinical benefits. Emerging preclinical studies report that nutrition-based interventions and glucose-regulating agents can improve therapeutic efficacy. However, the impact of such agents on therapeutic efficacy in metastatic kidney cancer remains unclear. Here, we examined acarbose, an alpha-glucosidase inhibitor and antidiabetic agent, in a preclinical model of metastatic kidney cancer. We found that acarbose blunted postprandial blood glucose elevations in lean, nondiabetic mice and impeded the growth of orthotopic renal tumors, an outcome that was reversed by exogenous glucose administration. Delayed renal tumor outgrowth in mice on acarbose occurred in a CD8 T cell-dependent manner. Tumors from these mice exhibited increased frequencies of CD8 T cells that retained production of IFNγ, TNFα, perforin, and granzyme B. Combining acarbose with either anti-PD-1 or the mammalian target of rapamycin inhibitor, rapamycin, significantly reduced lung metastases relative to control mice on the same therapies. Our findings in mice suggest that combining acarbose with current RCC therapeutics may improve outcomes, warranting further study to determine whether acarbose can achieve similar responses in advanced RCC patients in a safe and likely cost-effective manner.Keywords
Funding Information
- National Institutes of Health (R21CA223126)
This publication has 52 references indexed in Scilit:
- Increased Tumor Glycolysis Characterizes Immune Resistance to Adoptive T Cell TherapyCell Metabolism, 2018
- Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell CarcinomaNew England Journal of Medicine, 2018
- Metabolic Barriers to T Cell Function in TumorsThe Journal of Immunology, 2018
- Impact of oncogenic pathways on evasion of antitumour immune responsesNature Reviews Cancer, 2018
- LDHA-Associated Lactic Acid Production Blunts Tumor Immunosurveillance by T and NK CellsCell Metabolism, 2016
- Lactate Wreaks Havoc on Tumor-Infiltrating T and NK CellsCell Metabolism, 2016
- Rapalogs Efficacy Relies on the Modulation of Antitumor T-cell ImmunityCancer Research, 2016
- Caloric Restriction Mimetics Enhance Anticancer ImmunosurveillanceCancer Cell, 2016
- Immunological Effects of Conventional Chemotherapy and Targeted Anticancer AgentsCancer Cell, 2015
- Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trialThe Lancet, 2008